CPIX Cumberland Pharmaceuticals Inc.

$CPIX $SRPT Hey SRPT Board. I know we have disagreements before with CAPR but i definetly would put CPIX on the map. They are about to hold a national conference to provide a DMD cardiomyopathy update Monday after close. There is a chance FDA granted AA greenlight. They are a very tight float trading at a 120 million market cap and has 100 million cash and an active share buy back plus the CEO owns 38% of the company. There is only 15 million shares and the float if you subtract the institutions is around 6.1 million. Looking for $300 million to $500 million market cap if we get solid good news Monday. Good luck.

$CPIX $CAPR FDA has allowed CPIX to use historical data in their upcoming NDA for FULL approval (no phase 3 needed) is the very good sign that FDA has started to show their flexibility in approving rare disease. This is great news for both CPIX and CAPR !!! Even though CPIX and CAPR are reviewed under different FDA departments: CPIX is under CDER review. (not Prasad's department) CAPR is under CBER review.

$CPIX $SRPT AJ in urgent talks with FDA in September after CAPR debacle and got rolling NDA with filing expected this quarter after three year data for cardiomyopathy. Unfortunately most so-called investors need to be spoon fed and don't know what rolling NDA means. I don't need Crayola signs to know Cumberland's in the driver's seat. BULLISH‼️

$CPIX What matters are the fundamentals. It is very positive that the company is presenting a slide show in connection to the development of Ifetroban. There have been new developments which have taken place in the past two weeks which are favorable to Ifetroban. 1) Dr. Soslow, a Vanderbilt Pediatrician, Ifetroban trial investigator, author of medical research suggesting that LVEF and NT-ProBNP biomarker are predictive of mortality of DMD cardiomyopathy patients', was appointed to spearhead a D o D funded study which looks to develop models describing the path of cardiomyopathy in DMD patients 2) the FDA announced several steps it will be taking to encourage drug development in rare diseases. Pay attention to these facts and to the Monday company presentation.

$CPIX this morning in the "Advancing Cardiac Research in Duchenne" webinar it was mentioned that the FDA does not currently have a designated biomarker recognized for DMD cardiomyopathy making it hard to design a trial where cardio is the primary endpoint. There is a consortium of doctors meeting with the FDA in the next couple months to discuss DMD cardiomyopathy including trial designs. So maybe this is what we are waiting for ?

$CPIX if they do get approval that voucher will be worth around 15.00 share price alone.

$CPIX The scleroderma data was a dud--underpowered--but biomarkers were noted for study at a later date. Call it bad news, if it pleases; but make no mistake, the main event is Monday after close at 4:30pm Eastern. I, for one, anticipate very good data from the Company under AJ's leadership--who decided to pivot the course of the entire company back in April after running a commercial lineup he built personally over twenty plus years. Call me crazy, call me irresponsible, but I believe AJ has something good to share Monday regarding DMD cardiomyopathy. BULLISH‼️

$CPIX @ Roughly when do you think they publush the full 2 year and 3 year data sets for the 41 patient ole p2 studies on high dose ifetroban? Do you think we get a partnership?

$CPIX Monday is key to shareholders. It is not our base case that we receive AA now, but it is our base case that we will eventally receive AA. We do not expect news Monday of an FDA approved trial. However our base case is eventual AA, or worst case, an eventual FDA approved hybrid approach which includes a small study, and an opportunity to achieve approval based on 6 to 12 months of new data. On Monday, we expect favorable and durable 36 month data and an articulation of a path forward that relies in part on Dr. Soslow's published work and on the large DMD cardiomyopathy dataset he has accumulated to date. It may need to include the new data he is gathering from other entities, which will comprise an even bigger data set, as part of his newly funded D o D study. If AA Monday, company is worth north of 50 bucks per share. 30 bucks if a hybrid study is announced, 20 bucks if the long term data is good, and it is clear/probable that we will , in the near term, achieve AA. Good luck!

$CPIX Between a cheap better aspirin that cost $300 a year to manufacture versus CAPR cell therapy at $150K a year to manufacture the bet is clear.

$CPIX Management makes promise after promise that clinical trial data like DMD OLE or Scleroderma is "forthcoming" (definition: upcoming, approaching, impending, imminent, etc.). I'm 80 years old. Will I live to see any of this "imminent", etc. data? I think today's stock price and what it means is that management is good at promising but can't be trusted to deliver anything but more stalling bs instead of actual data. The FDA rewarded us with FAST track while management rewards stockholders with SLOW and SLOWER track progress and credibility. Patients need this drug TODAY! It needs to be in the hands of a much more competent and experienced drug company than SlOW track CPIX.

$CPIX If this company has analysts follow and on Wall Street's watch list, this stock is likely to be trading around $25 - $30 now ! This company is filing NDA for a potential block-buster drug, with $ 100 + MILLION cash in the bank. A a pipeline of potential block-buster drugs like: IPF and cancer ! this is YOU right now:

$CPIX this company has a healthy cash flow just about debt free with a very promising clinical trial. I just think Wall St is stupid and overreacts.

$CPIX Unbelievable... Trading below cash value again with no debt😅 No dilution risk here as the CEO hods 40% of the shares and with potentially skipping phase 3 no major cash burn in sight. Derisked as well now. What else can somebody ask for, except a better communication...

$CPIX As expected: Phase 3 meaning 4 more years waiting to see if the drug works ! if you have the patience, then wait..... They said FDA told them they did not have enough evidence for efficacy. Sadly, History data is not enough with this new FDA. Look at $CAPR

$CPIX this has big pharma buy out written all over in my opinion! I just got the feeling!

$CPIX they’re literally resubmitting the missing data. They have a rolling submission. Go read the updated news

$CPIX OLE must be strong to go straight to NDA with rolling submission, yet still selling off.

$CPIX $SRPT so Haha...define "national" call. This management team needs to button things up. "National" is unnecessary and meaningless. Promising safety and efficacy data and reneging after hours on a Friday is weak. Management is weak and inexperienced. The company management needs to up it ls game considerably. That includes hiring a CRO. Nevertheless we likely have an effective, safe drug in DMD.

$CPIX 374% already; congrats 🌷🌿🌟 Checkout $RXRX and $$GAU; long way to go for longs. Do your DD and get in.